These findings collectively demonstrated that GPN3 acted as an oncogene in NSCLC, which may be a potential diagnostic and prognostic biomarker for NSCLC, suggesting it may be a therapeutic target for NSCLC treatment. This evidence concerns the gene GPN3 and non-small cell lung carcinoma.